CNS/Neurology: Tiziana Life Sciences

About this session

Tiziana Life Sciences is focused on our main novel asset, foralumab, a fully human, anti-CD3 which is showing to reduce microglia activation in neuroinflammatory and neurodegenerative diseases through a simple nasal delivery device. Foralumab, a fully human anti-CD3 is delivered intranasally where it binds to the T-cell receptor complex in the cervical lymph node. This creates and activates Tregs. These Tregs then cross the blood brain barrier and regulate the innate immune system (microglia).

Speaker

• IE

  Ivor Elrifi

  CEO · Tiziana Life Sciences

  Speaker